Emerging Microbial-Resistant Pathogens: Updates on Clinical, Epidemiological, and Molecular Perspectives

Dear Colleagues,

The discovery of antimicrobials constitutes one of the most significant medical achievements of modern medicine; however, since the first decades of antibiotic introduction in clinical practice, microbes capable of evading clinically available antimicrobials have emerged, and currently, the development of antimicrobial resistance represents a serious threat to global health. Antimicrobial resistance is associated with higher medical costs, prolonged hospital stays, and increased mortality, and although this phenomenon can occur naturally, the inappropriate use of antimicrobials in humans and animals is a major factor that contributes to accelerating and aggravating the problem. Over the last few years, new resistance mechanisms have emerged, and the list of problematic antimicrobial-resistant microorganisms (AMRO) and multidrug-resistant organisms (MDRO) is growing. Especially concerning pathogens such as Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum β-lactamase (ESBLs) producing Gram-negative bacteria, carbapenem-resistant enterobacteriaceae (CRE), antimicrobial-resistant fungi (AMRF), multidrug-resistant tuberculosis (MDR-TB), and more recently, Candida auris are spreading worldwide and are increasingly detected in both the healthcare setting and in the community setting.

This Special Issue aims to expand the current knowledge about microbial-resistant pathogens (including MDRO, C. difficile, MRSA, VRE, ESBLs, and CRE). Suitable topics include epidemiological, clinical, and molecular studies (genomics, epigenomics, transcriptomics, and proteomics), as well as studies encompassing diagnosis, epidemiology, pathology, immunology, therapy, and monitoring. We encourage experts to discuss their experiences and results involving experimental studies using in vitro and in vivo models, including patient-derived xenograft animal models, as well as review articles.

Dr. Jorge Luis Espinoza
Dr. Cindy Shuan Ju Teh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antibiotic-resistant bacteria (ARB)
• multidrug-resistant organisms (MDRO)
• methicillin-resistant Staphylococcus aureus (MRSA)
• vancomycin-resistant enterococci (VRE)
• extended-spectrum β-lactamase (ESBLs) producing Gram-negative bacteria
• carbapenem-resistant enterobacteriaceae (CRE)
• extensively drug-resistant (XDR)
• pan drug-resistant bacteria
• Candida auris